First batch of Zhejiang University's 'Hundred Talents Program (Clinical Medicine)'
Second-tier talent of Zhejiang Province's '151 Talent Project'
Committee member of the Hematology Branch of the Zhejiang Medical Association
Committee member of the Fifth Committee of the Hematology Immunology Branch of the Chinese Society of Immunology
Studied at Mayo Clinic in the USA in 2019
Studied at Memorial Sloan-Kettering Cancer Center in the USA in 2022
Published 29 SCI papers as first author/corresponding author
Editor of the book 'Diagnosis and Treatment of Common Complications in Hematological Diseases'
2019 - Mayo Clinic, USA - Studied
2022 - Memorial Sloan-Kettering Cancer Center, USA - Studied
National Science and Technology Progress Award, Second Prize (2015): Innovation and application of key technologies for allogeneic hematopoietic stem cell transplantation
Ministry of Education Higher Education Science and Technology Progress Award, First Prize (2013): New technologies for early warning and diagnosis and treatment of important complications of allogeneic hematopoietic stem cell transplantation
Research
Mechanisms of leukemia occurrence and drug resistance Clinical and basic research on hematopoietic stem cell transplantation Clinical and basic research on cellular immunotherapy
The association of intestinal microbiota diversity and outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis, Wang Sh, Yue X, Zhou H, Chen X, Chen H, Hu L, Pan W, Zhao X, Xiao H*, 2023
Integrated genomic and single-cell transcriptomic analyses reveal clonal evolution and immune signature in donor cell leukemia after haploidentical allogeneic hematopoietic stem cell transplantation, Chen H, Zhao X, Pan W, Xiao H*, 2023
Daratumumab Prevents Experimental Xenogeneic Graft-versus-host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T cell Activation and Migration, Gao Y, Shan W, Gu T, Zhang J, Wu Y, Li X, Zeng X, Zhou H, Chen Z, Xiao H*, 2021
Engineering γδ T Cells: Recognizing and Activating on Their Own Way, Dong R, Zhang Y, Xiao H*, Zeng X*, 2022
CEBPA mutants down-regulate AML cell susceptibility to NK-mediated lysis by disruption of the expression of NKG2D ligands, which can be restored by LSD1 inhibition, Liu M, Du M, Yu J, Qian Z, Gao Y, Pan W, Zhao X, Wang M, Li H, Zheng J, Huang Q, Wang LM*, Xiao H*, 2022
Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: A phase III randomized controlled study, Zhang M, Xiao H, Shi J, Tan Y, Zhao Y, Yu J, Lai X, Hu Y, Zheng W, Luo Y, Huang H, 2021
A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy, Liu M, Zhao X, Pan W, Qian Z, Du M, Wang LM, Huang H*, Xiao H*, 2021
The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells, Wu K, Wang LM, Liu M, Xiu Y, Hu Y, Fu S, Huang H*, Xu B*, Xiao H*, 2021
Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature, Qian Y, Qian Z, Zhao X, Pan W, Wei X, Meng H, Yang L, Xiao H*, 2021
How Do We Manage Hematopoietic Cell Transplant during the SARS-CoV-2 Pandemic?, Xiao H, Luo Y, Shi J, Jin A, Mohty M, Nagler A, Gale RP, Huang H, 2021
High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials, Yu J, Du H, Ye X, Zhang L, Xiao H*, 2021
Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation, Pan W, Zhao X, Shi W, Jiang Z, Xiao H*, 2020
PTPN21-CDSlong isoform inhibits the response of acute lymphoblastic leukemia cells to NK-mediated lysis via the KIR/HLA-I axis, Wang H, Zhu N, Ye X, Wang L, Wang B, Shan W, Lai X, Tan Y, Fu S, Xiao H* and Huang H*, 2020
Haploinsufficiency of NR3C1 drives glucocorticoid resistance in adult acute lymphoblastic leukemia cells by down-regulating the mitochondrial apoptosis axis, and is sensitive to Bcl-2 blockage, Xiao H*, Ding Y, Gao Y, Wang LM, Wang H, Ding L, Li X, Yu X, Huang H*, 2019
Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia, Xiao H*, Li L, Pang Y, Wu Y, Jiang Z, Liu Z, Wu J, Xiao Y, Huang F, Liu Q, Zhang H, Luo Y, Huang H, 2018
Co-transplantation of haploidentical hematopoietic stem cell and allogeneic bone-marrow-derived mesenchymal stromal cells as a first-line treatment in very severe aplastic anemia patients with refractory infections, Yue C#, Ding Y#, Gao Y#, Li L, Pang Y, Liu Z, Zhang H, Xiao Y, Jiang Z, Xiao H*, 2018
Haploidentical hematopoietic SCT using helical tomotherapy for total-body irradiation and targeted dose boost in patients with high-risk /refractory acute lymphoblastic leukemia, Jiang Z#, Jia J#, Yue C, Pang Y, Liu Z, Ouyang L, Li H, Zhang J, Wen T, Li J, Li Z, Wang Y, Xiao Y*, Xiao H*, 2018
Allogeneic bone marrow-derived mesenchymal stromal cells expanded in vitro for treatment of aplastic anemia: a multicenter phase II trial, Pang Y#, Xiao H#, Zhang H, Liu Z, Li L, Gao Y, Li H, Jiang Z, Tan H, Lin J, Du X, Weng J, Nie D, Lin D, Zhang X, Liu Q, Xu D, Chen H, Ge X, Wang X, Xiao Y*, 2017
Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study, Tan Y#, Xiao H#, Wu D, Luo Y, Lan J, Liu Q, Yu K, Shi J, He J, Zheng W, Lai X, Zhu Y, Du K, Ye Y, Zhao Y, Zheng G, Hu Y, Han X, Zheng Y, Wei G, Cai Z, Huang H*, 2017
TNF-alpha enhances vascular cell adhesion molecule-1 expression in human bone marrow mesenchymal stem cells via the NF-kappaB, ERK and JNK signaling pathways, Lu Z#, Chen W#, Li Y#, Li L, Zhang H, Pang Y, Xiao Z, Xiao H*, Xiao Y*, 2016
Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells, Wang L#, Xiao H#, Zhang X, Liao W, Fu S, Huang H*, 2015
Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies, Zhu N#, Xiao H#, Wang LM, Fu S, Zhao C, Huang H*, 2015
T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT, Luo Y#, Xiao H#, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Zhu Y, Ye X, Yu X, Cai Z, Lin M, Huang H*, 2014
The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation, Wang L#, Xiao H#, Zhang X, Wang C, Huang H*, 2014
Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation, Xiao Y*#, Song J#, Jiang Z, Li Y, Gao Y, Xu W, Lu Z, Wang Y, Xiao H*, 2014
Donor TLR9 gene tagSNPs influence susceptibility to aGVHD and CMV reactivation in the allo-HSCT setting without polymorphisms in the TLR4 and NOD2 genes, Xiao H, Luo Y, Lai X, Shi J, Tan Y, He J, Xie W, Li L, Ye X, Yu X, Cai Z, Lin M, Huang H*, 2014
Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies, Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Zhang L, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H*, 2012
Area of Focus
Hematopoietic Stem Cell Transplantation | Clinical Research | Basic Research | Stem Cells | Applied Research | Immunotherapy | Clinical Application | Translational Research | Cellular Immunotherapy | Engineering Research
